Scope of the Study
Nasal polyps are fleshy swelling that develops in the lining of the nose and paranasal sinuses, the air-filled spaces that are linked to the nasal cavity. It varies in size and may be yellowish-brown or pink. It shaped like teardrops. Large nasal polyps or clusters can cause breathing difficulties and may affect the patientís sense of smell. It may block sinuses and cause problems. It cannot be cured but they can be treated with medications. Corticosteroid nasal sprays and pills are the most frequently used medications for treating nasal polyps. The antibiotics can be prescribed if the patient has a sinus infection caused by bacteria.
The market study is being classified, by Application (Hospitals, Clinics, Research Center and Other) and major geographies with country level break-up.
OptiNose US, Inc. (United States), Regeneron Pharmaceuticals, Inc. (United States), Merck KGaA (Germany), Pfizer, Inc. (United States), Roche Holding AG (Switzerland), Intersect ENT, Inc. (United States), GlaxoSmithKline plc. (United Kingdom), Novartis (United States), Sanofi (France) and Taro Pharmaceutical Industries Ltd. (United States) are some of the key players profiled in the study.
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Nasal Polyps Treatment market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Nasal Polyps Treatment market by Type, Application and Region.
On the basis of geography, the market of Nasal Polyps Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Medications will boost the Nasal Polyps Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis, the sub-segment i.e. CT Scan will boost the Nasal Polyps Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Symptoms, the sub-segment i.e. Runny Nose will boost the Nasal Polyps Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increase in the prevalence of ENT diseases
- Rising regulatory approvals for nasal polyp treatment
- Technological advancements in the treatment
- Side effects of the treatment of nasal polyps
- Rising number of hospitals and diagnostic centers worldwide
- Development of Healthcare Infrastructure in Emerging Economies
- No complete cure of nasal polyps available
On 26th June 2019, The United States Food and Drug Administration approved Dupixent (Dupilumab) to treat adults with nasal polyps accompanied by chronic rhinosinusitis. This is the first treatment approved for inadequately controlled chronic rhinosinusitis with nasal polyps.
Key Target AudienceNasal Polyps Treatment Providers, Research Professionals, Emerging Companies, Government Body & Associations and End-user
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase